Journey Medical (DERM) Competitors $7.33 +0.03 (+0.41%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$7.31 -0.02 (-0.27%) As of 10/3/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DERM vs. FBIO, PROK, AVBP, AKBA, MRVI, TBPH, DAWN, TYRA, GYRE, and PRMEShould you be buying Journey Medical stock or one of its competitors? The main competitors of Journey Medical include Fortress Biotech (FBIO), ProKidney (PROK), ArriVent BioPharma (AVBP), Akebia Therapeutics (AKBA), Maravai LifeSciences (MRVI), Theravance Biopharma (TBPH), Day One Biopharmaceuticals (DAWN), Tyra Biosciences (TYRA), Gyre Therapeutics (GYRE), and Prime Medicine (PRME). These companies are all part of the "medical" sector. Journey Medical vs. Its Competitors Fortress Biotech ProKidney ArriVent BioPharma Akebia Therapeutics Maravai LifeSciences Theravance Biopharma Day One Biopharmaceuticals Tyra Biosciences Gyre Therapeutics Prime Medicine Journey Medical (NASDAQ:DERM) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability. Is DERM or FBIO more profitable? Journey Medical has a net margin of -15.49% compared to Fortress Biotech's net margin of -24.84%. Journey Medical's return on equity of -48.69% beat Fortress Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Journey Medical-15.49% -48.69% -11.26% Fortress Biotech -24.84%-301.81%-27.48% Which has higher earnings and valuation, DERM or FBIO? Journey Medical has higher earnings, but lower revenue than Fortress Biotech. Journey Medical is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJourney Medical$56.13M3.44-$14.67M-$0.38-19.29Fortress Biotech$57.67M1.42-$46M-$1.05-2.62 Do analysts recommend DERM or FBIO? Journey Medical currently has a consensus target price of $12.17, indicating a potential upside of 65.98%. Fortress Biotech has a consensus target price of $16.50, indicating a potential upside of 500.00%. Given Fortress Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Journey Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Journey Medical 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20Fortress Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media refer more to DERM or FBIO? In the previous week, Fortress Biotech had 10 more articles in the media than Journey Medical. MarketBeat recorded 10 mentions for Fortress Biotech and 0 mentions for Journey Medical. Fortress Biotech's average media sentiment score of 0.26 beat Journey Medical's score of 0.00 indicating that Fortress Biotech is being referred to more favorably in the news media. Company Overall Sentiment Journey Medical Neutral Fortress Biotech Neutral Which has more volatility & risk, DERM or FBIO? Journey Medical has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500. Do institutionals and insiders believe in DERM or FBIO? 7.3% of Journey Medical shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 15.0% of Journey Medical shares are held by insiders. Comparatively, 27.9% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryFortress Biotech beats Journey Medical on 9 of the 16 factors compared between the two stocks. Get Journey Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DERM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DERM vs. The Competition Export to ExcelMetricJourney MedicalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$192.85M$2.63B$6.13B$10.58BDividend YieldN/A56.38%5.67%4.69%P/E Ratio-19.2924.2286.9626.71Price / Sales3.44726.66605.32131.81Price / CashN/A172.1237.9061.31Price / Book8.055.3412.556.55Net Income-$14.67M$32.92M$3.31B$277.50M7 Day Performance3.82%3.90%4.28%2.42%1 Month Performance4.56%8.79%6.90%8.63%1 Year Performance12.25%-3.79%70.54%31.60% Journey Medical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DERMJourney Medical1.6228 of 5 stars$7.33+0.4%$12.17+66.0%+12.3%$192.85M$56.13M-19.2990FBIOFortress Biotech2.6831 of 5 stars$3.90-0.3%$16.50+323.1%+68.7%$116.34M$57.67M-3.71170PROKProKidney3.1075 of 5 stars$2.48-0.4%$6.25+152.0%+61.7%$732.76M$527K-4.353AVBPArriVent BioPharma1.551 of 5 stars$18.16+0.7%$39.14+115.5%-27.2%$731.46MN/A-4.5240AKBAAkebia Therapeutics3.5297 of 5 stars$2.71-1.1%$6.75+149.1%+112.8%$726.50M$160.18M-15.94430Positive NewsMRVIMaravai LifeSciences3.5278 of 5 stars$2.83+0.4%$5.22+84.4%-60.8%$720.12M$259.18M-2.08610News CoveragePositive NewsOptions VolumeTBPHTheravance Biopharma3.3782 of 5 stars$14.43+2.6%$23.00+59.4%+77.9%$708.58M$64.38M60.13110Positive NewsDAWNDay One Biopharmaceuticals3.0381 of 5 stars$6.99+3.2%$25.29+261.7%-43.6%$693.46M$131.16M-7.3660TYRATyra Biosciences2.0552 of 5 stars$13.30+2.5%$31.86+139.5%-38.0%$691.26MN/A-7.4720Analyst UpgradeGYREGyre Therapeutics1.155 of 5 stars$7.50+4.7%$18.00+140.0%-45.0%$689.60M$105.76M750.7540PRMEPrime Medicine2.9473 of 5 stars$5.32+3.9%$8.92+67.6%+80.1%$689.02M$4.96M-2.60234 Related Companies and Tools Related Companies Fortress Biotech Competitors ProKidney Competitors ArriVent BioPharma Competitors Akebia Therapeutics Competitors Maravai LifeSciences Competitors Theravance Biopharma Competitors Day One Biopharmaceuticals Competitors Tyra Biosciences Competitors Gyre Therapeutics Competitors Prime Medicine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DERM) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Journey Medical Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Journey Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DERM Stock Alerts